Claudia Bonetti

Claudia Bonetti

Auto-generated profile, based on publicly available information

Claudia Bonetti

Ospedale Papa Giovanni XXIII: Aziende Socio Sanitarie Territoriale Papa Giovanni XXIII

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2025 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
CBClaudia Bonetti
Claudia Bonetti
ISIvan Silvestri
Ivan Silvestri
ACAlessio Caccioppola
Alessio Caccioppola
AMAndrea Meli
Andrea Meli
GGGiacomo Grasselli
Giacomo Grasselli
MPMauro Panigada
Mauro Panigada
Sepsis is a complex syndrome characterized by physiological, pathological, and biochemical abnormalities induced by infection, with up to 70% of patients experiencing coagulation alterations, ranging from subclinical coagulopathy to disseminated intravascular coagulation (DIC). The multifactorial nature of sepsis-related coagulopathy and the limitations of standard diagnostic parameters, such as platelet count and traditional coagulation tests, complicate its definition and management. Assessing coagulopathy related to sepsis presents significant challenges due to current definitions primarily focusing on diagnosing advanced stages of coagulation dysfunction, thereby overlooking the dynamic and evolving nature of the condition. Viscoelastic hemostatic assays (VHAs) have emerged as valuable tools in this context, offering real-time insights into clot formation, stabilization, and lysis by integrating both plasma and cellular contributions to coagulation. Data from clinical studies suggest that early stages of sepsis coagulopathy are characterized by hypercoagulability, while advanced stages may lead to hypocoagulability and DIC. Moreover, specific point-of-care assays can evaluate platelet performance in the clotting mechanism and potentially help the diagnosis of platelet dysfunction in sepsis. Additionally, the phenomenon of fibrinolysis inhibition contributes to the persistence of fibrin clots, promoting tissue ischemia and multiorgan dysfunction. Modified VHAs appear promising for detecting fibrinolysis impairment, which is associated with poorer outcomes, but the standardization of results is still a work in progress. Incorporating VHAs data into treatment strategies could lead to more targeted therapies, potentially improving outcomes in septic patients by addressing both hypercoagulable and hypocoagulable states, as well as fibrinolysis abnormalities. * These authors contributed equally to this article. Article published online: 24 May 2025 © 2025. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

10 November 2026 in Research Square
Verified
Preprint
Open access
PDF file
CBClaudia Bonetti
Claudia Bonetti
ISIvan Silvestri
Ivan Silvestri
ACAlessio Caccioppola
Alessio Caccioppola
AMAndrea Meli
Andrea Meli
GZGabriele Zimei
Gabriele Zimei
MPMauro Panigada
Mauro Panigada
Purpose: Sepsis-induced coagulopathy (SIC) involves a complex imbalance between coagulation activation and fibrinolysis inhibition, contributing to microvascular thrombosis and organ dysfunction. Conventional coagulation tests inadequately capture functional fibrinolytic alterations. The POCEFIS study used the ClotPro® tissue plasminogen activator (TPA) test to characterize fibrinolysis in septic patients and evaluate its clinical relevance and temporal evolution during the early phase of sepsis. Methods: In a cohort of septic intensive care unit (ICU) patients, fibrinolysis was assessed using the ClotPro® TPA-test at enrollment and on day 1, 2, 3 and 7 after enrollment. Specific plasma biomarkers (PAI-1, plasminogen, protein C, and protein S) were analyzed at enrollment and on day 2 and 7. Septic patients were classified according to temporal evolution of fibrinolytic status during the first three days of observation (normal versus impaired fibrinolysis). Results: At enrollment, impaired fibrinolysis was present in 38% of septic patients. However, considering the first three ICU days, 66% of patients exhibited fibrinolysis impairment. Impaired fibrinolysis was associated with higher lactate (4.2 mmol/L vs 2.9 mmol/L, p=0.0482), INR (1.5 vs 1.2, p=0.0156), and SOFA score (10.9 vs. 9.4, p=0.0282) at enrollment. Patients with impaired fibrinolysis showed persistently higher C-reactive protein and D-dimer values during the first week of observation (linear mixed-effects model, group effect p=0.0047 and p=0.0201). Conclusions: Fibrinolysis impairment is frequent, dynamic, and clinically relevant in sepsis. The ClotPro® TPA-test provides a global point-of-care evaluation of fibrinolysis. Serial viscoelastic assessment may improve risk stratification and support the development of individualized therapeutic strategies targeting SIC.